Browsing Over 191 Presentations

Sort By
Cancer neoantigens Educational session

Monitoring anti tumour T cell immunity

Lecture Time
11:20 - 11:40
Speakers
  • Pia Kvistborg
Session Name
Cancer neoantigens
Location
Room A, Geneva Palexpo, Geneva, Switzerland
Date
09.12.2017
Time
11:00 - 12:30
Authors
  • Pia Kvistborg
Cancer neoantigens Educational session

Deciphering the immunopeptidome of human cancers

Lecture Time
11:40 - 12:00
Speakers
  • Michal Bassani-Sternberg
Session Name
Cancer neoantigens
Location
Room A, Geneva Palexpo, Geneva, Switzerland
Date
09.12.2017
Time
11:00 - 12:30
Authors
  • Michal Bassani-Sternberg
Cancer neoantigens Educational session

Clonal neoantigens in cancer immunotherapy

Lecture Time
12:00 - 12:20
Speakers
  • Sergio Quezada
Session Name
Cancer neoantigens
Location
Room A, Geneva Palexpo, Geneva, Switzerland
Date
09.12.2017
Time
11:00 - 12:30
Authors
  • Sergio Quezada
Closing Keynote lecture Keynote Lecture

Learning from tumour microenvironment to inform therapy

Lecture Time
12:30 - 13:00
Speakers
  • George Coukos
Session Name
Closing Keynote lecture
Location
Room A, Geneva Palexpo, Geneva, Switzerland
Date
10.12.2017
Time
12:30 - 13:00
Authors
  • George Coukos
Combination of radiotherapy and immunocheckpoint inhibitors Educational session

Release the brake with checkpoint inhibitors

Lecture Time
11:40 - 12:00
Speakers
  • Inge Verbrugge
Session Name
Combination of radiotherapy and immunocheckpoint inhibitors
Location
Room C, Geneva Palexpo, Geneva, Switzerland
Date
08.12.2017
Time
11:00 - 12:30
Authors
  • Inge Verbrugge
Combination of radiotherapy and immunocheckpoint inhibitors Educational session

Optimal trial design for radiotherapy and immune treatment

Lecture Time
12:00 - 12:20
Speakers
  • Eric Deutsch
Session Name
Combination of radiotherapy and immunocheckpoint inhibitors
Location
Room C, Geneva Palexpo, Geneva, Switzerland
Date
08.12.2017
Time
11:00 - 12:30
Authors
  • Eric Deutsch
Combination of radiotherapy and immunocheckpoint inhibitors Educational session

Kick the immune system with immunocytokines

Lecture Time
11:20 - 11:40
Speakers
  • Dario Neri
Session Name
Combination of radiotherapy and immunocheckpoint inhibitors
Location
Room C, Geneva Palexpo, Geneva, Switzerland
Date
08.12.2017
Time
11:00 - 12:30
Authors
  • Dario Neri
Combining immune checkpoint inhibitors and VEGF targeted therapies in cancer treatment Proffered Paper Session

Primary PFS and safety analyses of a randomized Phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMpower150)

Presentation Number
LBA1_PR
Lecture Time
18:35 - 18:50
Speakers
  • Martin Reck
Session Name
Combining immune checkpoint inhibitors and VEGF targeted therapies in cancer treatment
Location
Room A, Geneva Palexpo, Geneva, Switzerland
Date
07.12.2017
Time
18:15 - 19:15
Authors
  • Martin Reck
  • Mark A. Socinski
  • Federico Cappuzzo
  • Francisco Orlandi
  • Daniil Stroyakovskii
  • Naoyuki Nogami
  • Delvys Rodríguez-Abreu
  • Denis Moro-Sibilot
  • Christian A. Thomas
  • Fabrice Barlesi
  • Gene Finley
  • Claudia Kelsch
  • Anthony Lee
  • Shelley Coleman
  • Yijing Shen
  • Marcin Kowanetz
  • Ariel Lopez-Chavez
  • Alan Sandler
  • Robert Jotte

Abstract

Background

Atezolizumab (atezo; anti–PD-L1) inhibits PD-L1 binding to PD-1 and B7.1, restoring anti-cancer immunity. Bev may further enhance atezo efficacy by inhibiting VEGF immunosuppression and promoting T-cell tumour infiltration. IMpower150 evaluates the addition of atezo to carboplatin (C) + paclitaxel (P) ± bevacizumab (bev) in chemo-naive patients (pts) with non-squamous (NSQ) mNSCLC.

Methods

1202 pts received atezo 1200 mg + C AUC 6 + P 200 mg/m2 (Arm A) or atezo + bev 15 mg/kg + C + P (Arm B) vs bev + C + P (Arm C) IV q3w for 4 or 6 cycles per investigator (INV) discretion, then maintenance atezo, atezo + bev or bev, respectively. Co-primary endpoints assessed at this data cutoff (15 Sep 2017; minimum follow up, 9.5 mo) were INV-assessed PFS in the ITT-WT (EGFR or ALK negative) population and in WT pts with expression of a tumour T-effector gene signature (Teff-WT; centrally assessed), and OS in the ITT-WT population, for the Arm B vs Arm C comparison. Due to pre-specified statistical testing hierarchy, Arm A vs Arm C has not been formally tested yet.

Results

356 pts in Arm B and 336 pts in Arm C were enrolled in the ITT-WT. Median age was 63 y; 60% were previous smokers (both arms). 61% and 62% were male, and 39% and 43% had ECOG PS 0 in Arms B and C, respectively. The HRs for INV-assessed PFS in Arm B vs C were 0.62 (95% CI: 0.52, 0.74; P < 0.0001) in the ITT-WT and 0.51 (0.38, 0.68; P < 0.0001) in the Teff-WT populations. Median PFS in Arm B vs C was 8.3 mo vs 6.8 mo and 11.3 mo vs 6.8 mo in the ITT-WT and Teff-WT populations, respectively. PFS benefit was seen regardless of PD-L1 IHC status, including PD-L1–negative pts (TC0/IC0; HR, 0.77 [95% CI: 0.61, 0.99]). Landmark PFS and ORR are shown (Table). Arm B had a comparable safety profile to Arm C; treatment-related serious AEs were 25% vs 19%, respectively.

Conclusions

IMpower150 is the first Ph 3 study to show a statistically significant and clinically meaningful PFS benefit with atezo + bev + chemo vs bev + chemo in pts with 1L NSQ mNSCLC.

Table. IMpower150 Primary PFS Analysis, landmark PFS and ORR

Arm C
(bev + C + P;
N = 400)

Arm B
(atezo + bev + C + P;
N = 400)

ITT-WT populationa

n = 336

n = 356

Median PFS (95% CI), mo

6.8 (6.0, 7.1)

8.3 (7.7, 9.8)

HR (95% CI; P value)

0.62 (0.52, 0.74; P < 0.0001)

ITT-WT landmark PFS (95% CI), %

6-month

56% (51, 62)

67% (62, 72)

12-month

18% (13, 23)

37% (31, 42)

ORRb,c (95% CI), %

48% (43, 54)

64% (58, 68)

Teff-WT populationa

n = 129

n = 155

Median PFS (95% CI), mo

6.8 (5.9, 7.4)

11.3 (9.1, 13.0)

HR (95% CI; P value)

0.51 (0.38, 0.68; P < 0.0001)

Teff-WT landmark PFS (95% CI), %

6-month

57% (48, 66)

72% (65, 79)

12-month

18% (10, 25)

46% (38, 54)

ORRb,d (95% CI), %

54% (44, 62)

69% (61, 76)

DOR, duration of response; HR, hazard ratio; ORR, objective response rate; PFS, progression-free survival; Teff, T-effector; WT, wild-type.
a WT populations exclude patients with EGFR or ALK driver mutations.
b Unconfirmed ORR. c n = 353 in Arm B and n = 331 in Arm C. d n = 153 in Arm B and n = 127 in Arm C.
NCT02366143

Clinical trial identification

NCT02366143

Collapse
Combining immune checkpoint inhibitors and VEGF targeted therapies in cancer treatment Proffered Paper Session

The immunogenic effects of VEGF targeted therapy: Fact or fiction?

Lecture Time
18:15 - 18:35
Speakers
  • Thomas Powles
Session Name
Combining immune checkpoint inhibitors and VEGF targeted therapies in cancer treatment
Location
Room A, Geneva Palexpo, Geneva, Switzerland
Date
07.12.2017
Time
18:15 - 19:15
Authors
  • Thomas Powles
Combining immune checkpoint inhibitors and VEGF targeted therapies in cancer treatment Proffered Paper Session

Invited Discussant LBA1_PR

Lecture Time
18:50 - 19:05
Speakers
  • Solange Peters
  • Naiyer Rizvi
Session Name
Combining immune checkpoint inhibitors and VEGF targeted therapies in cancer treatment
Location
Room A, Geneva Palexpo, Geneva, Switzerland
Date
07.12.2017
Time
18:15 - 19:15
Authors
  • Solange Peters
  • Naiyer Rizvi
Designing immune oncology clinical trials: Opportunities and hurdles Educational session

Response, progress and survival as endpoints for immuno-oncology therapy trials

Lecture Time
16:15 - 16:35
Speakers
  • Naiyer Rizvi
Session Name
Designing immune oncology clinical trials: Opportunities and hurdles
Location
Room A, Geneva Palexpo, Geneva, Switzerland
Date
08.12.2017
Time
16:15 - 18:05
Authors
  • Naiyer Rizvi
Designing immune oncology clinical trials: Opportunities and hurdles Educational session

How can we obtain accurate efficacy data from early phase trials

Lecture Time
16:35 - 16:55
Speakers
  • Thomas Powles
Session Name
Designing immune oncology clinical trials: Opportunities and hurdles
Location
Room A, Geneva Palexpo, Geneva, Switzerland
Date
08.12.2017
Time
16:15 - 18:05
Authors
  • Thomas Powles